Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account

Table of contents

DetailsRelated

Exhibit 13(a) - Methodology for Librela FDA CVM Adverse Event Analysis Through Q4 2025

FDA-2026-P-6249-0021Supporting & Related Material
Document

Details

The document's own metadata, straight from the source system.

Title
Exhibit 13(a) - Methodology for Librela FDA CVM Adverse Event Analysis Through Q4 2025
Posted
Jun 3, 2026
Agency
Food and Drug Administration (FDA)
Topics
View on regulations.gov ↗